Article

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot Study

2026-03-05

Abstract excerpt

<h4>Background: </h4> Small-cell lung cancer (SCLC) represents an aggressive malignancy associated with a poor prognosis, underscoring the critical demand for enhanced monitoring methodologies. Circulating tumor DNA (ctDNA) constitutes a promising non-invasive biomarker; however, reports employing highly sensitive, tumor-informed assays in SCLC remain scarce. This investigation aimed to assess the clinical utility...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3c58641a-df55-504b-8d36-8ab20507dbb0
DOI: 10.20944/preprints202603.0468.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot StudyDOI 10.20944/preprints202603.0468.v1Read

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.Semantic proximity Read

Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical utility studySemantic proximity Read

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung CancerSemantic proximity Read

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.Semantic proximity Read

Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.Semantic proximity Read

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity Read

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancerSemantic proximity Read

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.Semantic proximity Read